ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer
July 16, 2024 16:59 ET
|
ORIC Pharmaceuticals
ORIC-944, a potential best-in-class PRC2 inhibitor, is being evaluated in combination with darolutamide and in combination with apalutamide in patients with mCRPC ORIC entered into clinical trial...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 05, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 07, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, June 07, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
May 29, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
May 06, 2024 16:05 ET
|
ORIC Pharmaceuticals
Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC patients with EGFR exon 20 insertion, HER2 exon 20 insertion, or EGFR atypical mutations; updated Phase 1b data expected in the first half...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO and SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address...
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
April 15, 2024 16:15 ET
|
ORIC Pharmaceuticals
Initiated multiple Phase 1b expansion cohorts to determine the RP2D of ORIC-114 in NSCLC patients with EGFR exon 20, HER2 exon 20, or EGFR atypical mutations Additionally, the company initiated an...
ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024 08:00 ET
|
ORIC Pharmaceuticals
ORIC-944, a potent and selective allosteric PRC2 inhibitor, demonstrates superior preclinical drug properties and longer clinical half-life which supports a potential best-in-class profile versus...
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that...
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
April 04, 2024 16:30 ET
|
ORIC Pharmaceuticals
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that...